Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 470-470-3 | CAS number: 9022-75-7
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
In a reverse gene mutation assay in bacteria, performed according to the OECD guideline 471, in compliance with GLP, CHIMEXANE NV was found not to be mutagenic in S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102 with and without metabolic activation.
In an in vitro chromosome aberration test performed with human primary lymphocytes according to OECD guideline 473 and in compliance with GLP, CHIMEXANE NV did not induce chromosome aberrations in cultured human lymphocytes with and without metabolic activation.
In an in vitro micronucleus test conducted according to OECD guideline 487 and in compliance with GLP, CHIMEXANE NV was negative in L5178Y TK+/- mouse lymphoma cells with and without metabolic activation.
In an in vitro mammalian cell gene mutation test conducted with L5178Y mouse lymphoma cells according to OECD guideline 476 and in compliance with GLP, CHIMEXANE NV did not induce mutation at the tk locus of L5178Y mouse lymphoma cells in the absence and presence of a rat liver metabolic activation system.
Justification for selection of genetic toxicity endpoint
No robust study summary was chosen for this endpoint because more than one study was used to complete this endpoint.
Short description of key information:
CHIMEXANE NV was found not to be mutagenic in S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102, it did not induce chromosome aberrations in cultured human lymphocytes and it did not induce mutation at the tk locus of L5178Y mouse lymphoma cells.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
As Chimexane NV was negative in an in vitro reverse gene mutation assay in bacteria, an in vitro chromosome aberration test and in an in vitro mammalian cell gene mutation test, it is not classified as mutagenic according to Annex VI to the Directive 67/548/EEC and in CLP Regulation (EC) N° (1272-2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
